| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activists step in to deliver PEP and PrEP in Mexico
|
Pebody, Roger
|
|
|
12 |
9 |
p. e614
|
artikel
|
| 2 |
A moment of reckoning
|
The Lancet HIV,
|
|
|
12 |
9 |
p. e603
|
artikel
|
| 3 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial
|
Severe, Patrice
|
|
|
12 |
9 |
p. e616-e626
|
artikel
|
| 4 |
Do we need routine integrase resistance testing before starting antiretroviral therapy?
|
Kantor, Rami
|
|
|
12 |
9 |
p. e664-e668
|
artikel
|
| 5 |
Ending paediatric AIDS: time to close implementation gaps
|
Yotebieng, Marcel
|
|
|
12 |
9 |
p. e607-e608
|
artikel
|
| 6 |
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process
|
Orkin, Chloe
|
|
|
12 |
9 |
p. e649-e659
|
artikel
|
| 7 |
Funding concerns pervasive at IAS 2025
|
Adepoju, Paul
|
|
|
12 |
9 |
p. e611
|
artikel
|
| 8 |
Highlights of the 13th IAS Conference on HIV Science
|
Hayward, Peter
|
|
|
12 |
9 |
p. e613
|
artikel
|
| 9 |
Optimised second-line regimens in the public health approach
|
Paton, Nicholas I
|
|
|
12 |
9 |
p. e604-e605
|
artikel
|
| 10 |
Predictors of treatment-emergent resistance to dolutegravir
|
McCluskey, Suzanne M
|
|
|
12 |
9 |
p. e660-e663
|
artikel
|
| 11 |
Prioritising HIV drug resistance testing according to risk
|
van Zyl, Gert U
|
|
|
12 |
9 |
p. e605-e607
|
artikel
|
| 12 |
Probability of vertical HIV transmission: a systematic review and meta-regression
|
Walters, Magdalene K
|
|
|
12 |
9 |
p. e638-e648
|
artikel
|
| 13 |
Retiring the language of first-line and second-line ART
|
Vitoria, Marco
|
|
|
12 |
9 |
p. e608-e610
|
artikel
|
| 14 |
The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir–lamivudine–dolutegravir in South Africa: a modelling study
|
Hyle, Emily P
|
|
|
12 |
9 |
p. e627-e637
|
artikel
|
| 15 |
Tragic social history of HIV/AIDS in 1980s rural France
|
Burki, Talha
|
|
|
12 |
9 |
p. e615
|
artikel
|
| 16 |
WHO recommends lenacapavir for HIV prevention
|
Pebody, Roger
|
|
|
12 |
9 |
p. e612
|
artikel
|
Tijdschrift beschrijving